Leveraging microbiology nudges to promote antimicrobial stewardship in acute care settings

Michael P. Veve¹, Rachel M. Kenney¹, Amy Beaulac², Erin Eriksson³, Anita B. Shallal⁴, Robert J. Tibbetts⁵, Kathy Callahan⁵, Geehan Suleyman⁴, Linoj Samuel⁵

¹Department of Pharmacy, Henry Ford Hospital, Detroit, MI, USA; ²Department of Pharmacy, Henry Ford West Bloomfield Hospital, West Bloomfield, MI, USA; ³Department of Pharmacy, Henry Ford Jackson Hospital, Jackson, MI, USA; ⁴Department of Infectious Diseases, Henry Ford Hospital, Detroit, MI, USA; ⁵Department of Microbiology, Henry Ford Hospital, Detroit, MI, USA

BACKGROUND

- Microbiology comments, or "nudges", are efficient, effective, and sustainable stewardship interventions that can be reproduced in most settings
- By strategically reporting microbiology results while maintaining prescriber autonomy, nudging strategies

CRAFTING A THOUGHTFUL NUDGE

Where could a nudge be useful to improve patient care? What internal data do you have?

> **Example 1.** "Appropriate de-escalation of antibiotic therapy for pneumonia is best practice, but prescribers often fail to act on cultures reported as commensal flora or misinterpret such results."

Develop a thoughtful nudge, provide interpretive education to clinicians





within the electronic medical record are effective in improving antimicrobial use

OBJECTIVE

To describe three best practice examples of developing purposeful microbiology nudges that improve antimicrobial prescribing in acute care settings

Evaluate Findings – Antibiotic De-escalation Pre-intervention & Post-Intervention



RESULTS

Example 2. Another Respiratory Culture Nudge Improves Pneumonia Prescribing

Antibiotic Prescribing in *H. influenzae* and *M. catarrhalis*

Organism	β-lactamase Result	Suboptimal De-escalation
H. influenzae	Positive, <i>n</i> =5	25%
H. Influenzae	Negative, <i>n</i> =13	0%
M. catarrhalis	Positive, <i>n</i> =12	33%

Example 3. Appending a Blood Culture Nudge to Rapid PCR Results Improves Prescribing in Low- and No-risk AmpC Enterobacterales

We aimed to change prescribing practices for treatment of no/low risk AmpC Enterobacterales across Henry Ford Health hospitals to use narrower spectrum therapy vs. cefepime/carbapenems and achieve the same patient outcomes



Eliminated an AmpC comment in the electronic medical record microbiology report for low/no risk organisms: *Citrobacter koseri*, Citrobacter amalonaticus, Serratia marcescens, Morganella morganii, and Providencia species (22 March 2022)

Post-comment

			S							
					Haemophilus influenzae					
	Dro	comm	ont			Antibiotic	Interpretation	Value	Method	
	Pie	-comm	em			Beta Lactamase	Resistant	Positive	BLC (BETA LACTAMASE)	
Suscepti	bility					Beta Lactamase		This organism is	BLC (BETA	
Manualla asteribalia							predictably susceptible	LACTAMASE)		
Moraxella catarrhalis							to			
Anubio Bata La	-t	Pasistent	Desitive					Ampiciliin/Subactam		
Beta La	ctamase	Resistant	Positive					Amovicillin/Clavulanate		
				LACTAMASE				oral.		
						Manage II. and a ball				
Haemophilus influenzae						Interpretation	Valua	Mathod		
Antibioti	C	Interpretation	Valu	e Method		Reta Lactamase	Resistant	Positive		
Beta Lac	tamase	Susceptible	Negative	BLC (BETA		beta Lactamase	Resistant	POSITIVE	LACTAMASE)	
	LACTAMASE)				Beta Lactamase		This organism is	BLC (BETA		
								predictably susceptible	LACTAMASE)	
								to		
								Ampicillin/Sulbactam		
								IV or		
								Amoxicillin/Clavulanate		
					-			orai.		
	Optimal Antibiotic De-escalation									
Ontimal										
Optimal										





Revised Tier 1: Rapid blood polymerase chain reaction (PCR) identification guideline and modified BioFire® Blood Culture Identification (BCID2) Panel PCR microbiology comment for *Serratia marcescens* recommending ceftriaxone as the treatment of choice (29 June 2022)



Developed a one-page guidance document and provided education in person and electronically for pharmacists and prescribers (2nd quarter 2022)

Serratia marcescens microbiology comment before intervention:

Anaerobic bottle Serratia marcescens Susceptibility to follow Presumed AmpC beta-lactamase producer. Drugs of choice = Cefepime or Ertapenem.

Serratia marcescens microbiology comment after intervention:

Aerobic bottle Serratia marcescens Susceptibility to follow Drug of choice = Ceftriaxone !

Definitive Antibiotic Treatment for low/no risk AmpC Enterobacterales



SUMMARY

- Nudge success relies on collaborative efforts among microbiology and antimicrobial stewardship personnel
- Nudge roll-out should include i) clinician education, ii) policy change and/or end-user buy-in, and iii) formal evaluation for effectiveness
- Future Henry Ford Health nudge directions include i) appending "therapy of choice" antibiotic recommendations based on BIOFIRE[®] Blood Culture Identification (BCID2) Panel panel results and ii) recommending no antibiotic treatment for common colonizing bacteria

REFERENCES

- Infect Control Hosp Epidemiol 40:1400–1406.
- Open Forum Infect Dis. 2017 Oct 4;4(Suppl 1):S28.
- Antimicrob Steward Healthc Epidemiol. 2023 Feb 2;3(1): 10.1017/ash.2023.1.
- Antimicrob Agents Chemother. 2023 Nov 15;67(11):e0082623.
- Antimicrob Steward Healthc Epidemiol. 2022 Jan 31;2(1):e15.

